154 related articles for article (PubMed ID: 32384200)
1. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
[TBL] [Abstract][Full Text] [Related]
2. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
[TBL] [Abstract][Full Text] [Related]
3. Role of P53 and MDM2 in treatment response of human germ cell tumors.
Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2002 Mar; 20(6):1551-61. PubMed ID: 11896104
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression.
Saeednejad Zanjani L; Razmi M; Fattahi F; Kalantari E; Abolhasani M; Saki S; Madjd Z; Mohsenzadegan M
J Cancer Res Clin Oncol; 2022 Mar; 148(3):609-631. PubMed ID: 34837545
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
7. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G
Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract][Full Text] [Related]
9. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
[TBL] [Abstract][Full Text] [Related]
10. Brachyury oncogene is a prognostic factor in high-risk testicular germ cell tumors.
Pinto F; Cárcano FM; da Silva ECA; Vidal DO; Scapulatempo-Neto C; Lopes LF; Reis RM
Andrology; 2018 Jul; 6(4):597-604. PubMed ID: 29749711
[TBL] [Abstract][Full Text] [Related]
11. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors.
Li B; Cheng Q; Li Z; Chen J
Cell Cycle; 2010 Apr; 9(7):1411-20. PubMed ID: 20372076
[TBL] [Abstract][Full Text] [Related]
12. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.
Jeczen R; Skomra D; Cybulski M; Schneider-Stock R; Szewczuk W; Roessner A; Rechberger T; Semczuk A
Clin Exp Metastasis; 2007; 24(7):503-11. PubMed ID: 17671841
[TBL] [Abstract][Full Text] [Related]
13. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
[TBL] [Abstract][Full Text] [Related]
14. Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins.
Spinos T; Zografos E; Koutsoukos K; Zagouri F; Kosmas C; Driva TS; Goutas D; Gakiopoulou C; Agrogiannis G; Theochari E; Tzavara C; Lazaris AC
Int Urol Nephrol; 2024 Jun; 56(6):1887-1898. PubMed ID: 38285100
[TBL] [Abstract][Full Text] [Related]
15. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
16. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
[TBL] [Abstract][Full Text] [Related]
18. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
19. Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression.
Miyai K; Yamamoto S; Asano T; Tamai S; Matsubara O; Tsuda H
Cancer Sci; 2010 Sep; 101(9):1970-6. PubMed ID: 20608935
[TBL] [Abstract][Full Text] [Related]
20. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]